Biogen (MIL:1BIIB) Other Current Liabilities : €178 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Biogen Other Current Liabilities?

Biogen's other current liabilities for the quarter that ended in Mar. 2025 was €178 Mil.

Biogen's quarterly other current liabilities declined from Sep. 2024 (€834 Mil) to Dec. 2024 (€359 Mil) and declined from Dec. 2024 (€359 Mil) to Mar. 2025 (€178 Mil).

Biogen's annual other current liabilities declined from Dec. 2022 (€1,079 Mil) to Dec. 2023 (€307 Mil) but then increased from Dec. 2023 (€307 Mil) to Dec. 2024 (€359 Mil).

Biogen Other Current Liabilities Historical Data

The historical data trend for Biogen's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Other Current Liabilities Chart

Biogen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Current Liabilities

Get a 7-Day Free Trial

423.58

305.41

1,078.52

307.29

358.89

Biogen Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Current Liabilities	Get a 7-Day Free Trial															808.59	852.64	834.42	358.89	177.88

Biogen Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Biogen Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Biogen's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MIL:1BIIB) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico BIIB_KZ:Kazakhstan 0R1B:UK IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Biogen Headlines

No Headlines